Literature DB >> 8380737

Expression of HGF-SF in normal and malignant human tissues.

R Zarnegar1, M C DeFrances.   

Abstract

Hepatocyte Growth Factor (HGF) also known as Scatter Factor (SF) is a multifunctional cytokine that primarily acts on epithelial cells. Its effects range from enhancement of cell proliferation and cell growth, stimulation of cell migration and motility, promotion of angiogenesis and morphogenesis to inhibition of tumor cell growth. HGF-SF and its receptor proto-oncogene c-met are expressed in a variety of normal embryonic and adult tissues of mouse, rabbit, rat, human and probably other vertebrates. Though the precise physiological function of this cytokine is not understood presently, a large body of experimental data is being rapidly compiled which may help to elucidate the role of HGF-SF in normal and abnormal growth and development. The goal of this chapter is to discuss the current knowledge concerning HGF-SF expression in normal and malignant tissues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380737

Source DB:  PubMed          Journal:  EXS        ISSN: 1023-294X


  8 in total

1.  The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Authors:  S Koochekpour; M Jeffers; P H Wang; C Gong; G A Taylor; L M Roessler; R Stearman; J R Vasselli; W G Stetler-Stevenson; W G Kaelin; W M Linehan; R D Klausner; J R Gnarra; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

Review 2.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase.

Authors:  K A Furge; D Kiewlich; P Le; M N Vo; M Faure; A R Howlett; K E Lipson; G F Vande Woude; C P Webb
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

4.  A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor.

Authors:  Florian Schelter; Julia Kobuch; Marcia L Moss; J David Becherer; Paolo M Comoglio; Carla Boccaccio; Achim Krüger
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

Review 5.  Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.

Authors:  Ming-Hai Wang; Snehal S Padhye; Sunny Guin; Qi Ma; Yong-qing Zhou
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 6.  Growth factor regulation of integrin-mediated cell motility.

Authors:  K Matsumoto; B L Ziober; C C Yao; R H Kramer
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

7.  Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

Authors:  P A Humphrey; X Zhu; R Zarnegar; P E Swanson; T L Ratliff; R T Vollmer; M L Day
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

8.  MET expression during prostate cancer progression.

Authors:  Esther I Verhoef; Kimberley Kolijn; Maria J De Herdt; Berdine van der Steen; A Marije Hoogland; Hein F B M Sleddens; Leendert H J Looijenga; Geert J L H van Leenders
Journal:  Oncotarget       Date:  2016-05-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.